[Ophthalmological experiences with the xanthine compound BL 191 (author's transl)].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002829:Choroid / Q000098:blood supply; D005123:Eye / Q000098:blood supply; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007659:Ketones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009900:Optic Nerve / Q000098:blood supply; D012039:Regional Blood Flow / Q000187:drug effects; D012171:Retinal Vessels / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects; D014970:Xanthines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D007659:Ketones; D014665:Vasodilator Agents; D014970:Xanthines
Ophthalmologische Erfahrungen mit dem neuen Xanthinkörper BL 191.